Tikva Allocell
Summary active Updated Jul 24, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Tikva Allocell is a Singapore-based biotechnology company developing engineered, donor-derived (allogeneic) cell therapies for solid tumors 123. Its lead candidate, TAVST01, targets B7-H3-positive solid tumors — including lung, breast, prostate, pancreatic, and pediatric cancers — by combining Epstein-Barr virus (EBV)-specific T cells with a B7-H3-targeting receptor and SerpinB9 protein engineering intended to help the cells resist immune rejection 12. The technology platform is licensed exclusively from Baylor College of Medicine, with scientific advisors including Malcolm Brenner, Cliona Rooney, and Helen Heslop 12. The company is led by CEO Ivan Horak 12.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-07-22 | Series A | $8M | Kantharos Capital | – 123 |
Proceeds will fund IND-enabling activities and support a planned year-end 2026 Investigational New Drug submission for TAVST01, with Phase 1 clinical trials planned in Singapore and the United States 12.
What Investors Say
No independently sourced investor commentary found beyond the announcement press release.
What Founders Say
No independently sourced founder testimonials found at this time.
Sources
-
Yahoo Finance, “Tikva Allocell Closes $8 Million Series A Financing to Advance Engineered EBV-Specific T-Cell Therapy for Solid Tumors,” July 22, 2026. Accessed July 24, 2026. https://finance.yahoo.com/healthcare/articles/tikva-allocell-closes-8-million-110300629.html↩↩↩↩↩↩
-
TNGlobal, “Singapore’s Tikva Allocell raises $8M in Series A financing led by Kantharos Capital,” July 23, 2026. Accessed July 24, 2026. https://technode.global/2026/07/23/singapores-tikva-allocell-raises-8m-in-series-a-financing-led-by-kantharos-capital/↩↩↩↩↩↩
-
FinSMEs, “Tikva Allocell Raises $8M in Series A Funding,” July 2026. Accessed July 24, 2026. https://www.finsmes.com/2026/07/tikva-allocell-raises-8m-in-series-a-funding.html↩↩